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SUMMARY  
 
A novel administration strategy of immunoglobulin treatment is represented 
by injection of recombinant human hyaluronidase (rHUPH20) with 
subcutaneous immunoglobulins. The use of facilitated subcutaneous 
Immunoglobulin Treatment (fSCIG) for the treatment of autoimmune 
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conditions is yet to be investigated. 
We present the case of a 56-years old female patient with pemphigus vulgaris 
predominantly of the oral mucous membranes, previously treated for 24 
months with azathioprine and medium-doses of steroids, with only partial 
remission. When she came to our attention, a concomitant newly diagnosis of 
infiltrating ductal breast cancerlimited the use of immunosuppressive agents. 
She was started with fSCIG (25 g/montly).  After 18 months of follow-up, her 
breast cancer has been successfully treated and a substantial decrease of the 
rate of bullous mucous lesions and improvement of time to lesion healing and 
resolution was observed. 
fSCIG might represent an steroid-sparing tool for the treatment of selected 
cases of pemphigus vulgaris.  
BACKGROUND  
 
Immunoglobulin treatment has been investigated in numerous autoimmune 
conditions, especially due to their safe profile and simple administration. 
Indeed, immunoglobulin treatment is particularly appealing when the use of 
other immunosuppressive strategies is limited due to concomitant conditions, 
such infection or malignancy [1][2].  
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A novel administration strategy of immunoglobulin treatment is represented 
by injection of recombinant human hyaluronidase (rHUPH20) with 
subcutaneous immunogobulins (SCIG) that facilitate SCIG treatment (fSCIG). 
This enzyme facilitates drug dispersion and absorption by increasing the 
hydraulic conductivity in the interstitium. Therefore, fSCIG have the 
advantages of having the possibility of higher IgG injection rates, 
bioavailability and increased infusion volumes [3]. rHUPH20 is short acting, 
with a short half life (<30 minutes), which entails a prompt tissue restoration 
(24-48h) [4]. In addition, rHUPH20 induces only modest immunogenicity 
which has no association with adverse events [5].  
fSCIG treatment presents many advantages for patients that undergo 
immunoglobulin therapy. Compared to intravenous immunoglobulins (IVIG), 
fSCIG can be a self-injected at home, improving the quality of life of the 
patients. Furthermore, considering IVIG, the rate of systemic adverse reactions 
is significantly lower [5]. When comparing SCIG treatment alone, fSCIG are 
injected less frequently (1-2 weeks vs monthly infusions), in a single site with 
an overall better bioavailability, higher IgG injection rates and increased 
injection volumes. 
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The use of Immunoglobulin therapy for autoimmune conditions has been 
proven and analyzed in numerous trials [6], however, the potential use of 
fSCIG has yet to be investigated. We hereby present a case of a patient with 
pemphigus vulgaris treated in our center with fSCIG.  
 
CASE PRESENTATION  
 
We present the case of a 56 years old female patient with biopsy proven 
pemphigus vulgaris predominantly of the oral mucous membranes (Anti-
Desmoglein D1 0,85 U/ml and Anti-Desmoglein D3 145,4 U/ml). 
After the diagnosis in 2015, the patient has been treated over the years with 
oral steroids (25 to 12.5 mg prednisone daily ) and azathioprine (50-100 mg 
daily), with only partial response. 
When she came to our attention, the patient presented with a concomitant 
newly diagnosis of infiltrating ductal breast cancer and she was on 12.5mg 
corticosteroids daily. She successfully underwent excision surgery with 
axillary lymph node biopsy and radiotherapy. Taking into account the clinical 
and biological features of the lesion, treatment with tamoxifene 20 mg (1 cp / 
day) associated with GnRh analogue treatment was started.  
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While undergoing the treatment for the malignancy, the patient experienced a 
considerable worsening of the autoimmune condition, with increased rate of 
bullous lesion and duration, while on solely steroid treatment.  
INVESTIGATIONS 
 
The  undergone relevant investigation are resumed in Table 1. 
 
 
DIFFERENTIAL DIAGNOSIS  
 
Differential diagnosis included Paraneoplastic Pemphigus, which is a rare 
autoimmune mucocutaneous blistering disease associated with an underlying 
malignancy. It is thought to be caused by antibodies to tumor antigenscross-
reacting with epithelial antigens, specifically desmosomal and 
hemidesmosomal antigens [7]. 
 
TREATMENT  
 
Due to the concomitant diagnosis of infiltrating breast cancer, the 
immunosuppressive therapy was suspended. Possible  available therapeutic 
options were screened, including anti-CD20 B-cell depletion therapy, to date 
considered a therapy of choice in similar cases. However, due to the history of 
malignancies and to address the specific request of the patient to drastically 
reduce her hospitalization time, she was started with fSCIG (25 g; 
0.36g/kg/month) at monthly cycles, in one injection. After initially trained at 
our centre, the patient began to undergo home-based monthly therapeutic 
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cycles. 
The patient was closely follow-up with monthly clinical and laboratory 
monitoring  
 
 
OUTCOME AND FOLLOW-UP  
 
The patient was follow-up for 18 months, with substantial decrease of the rate 
of bullous mucous lesions: the rate of lesions decreased from one new weekly 
lesion to one every three weeks. There was also an improvement of time to 
lesion healing and resolution: one week to ten days with sole steroid therapy 
v.s. three to four days with fSCIG.  
Figure 1 illustrates the resolution of a bullous lesion within just 2 days.  
After four months, steroid treatment was tapered down during the course of 
two months, down to 7,5 mg of corticosteroids. Of note, before starting the 
therapy with fSCIG, she has never been able to taper her prednisone dose 
below 12.5 mg daily due to the frequency of her oral lesions.  
 
DISCUSSION  
 
Pemphigus vulgaris is a rare and life-threatening disease and patients suffer 
from a debilitating quality of life[8]. The treatment goal in patients with 
pemphigus vulgaris is to induce and maintain remission, which clinically 
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corresponds to cessation of new blister formation, healing of old wounds and 
to eventually complete the tapering of steroid treatment [9]. 
Recently, Wasserman et al in a phase III study [10] and in its extension study 
[11] demonstrated that fSCIG have equivalent efficacy, safety profile and 
overall pharmacokinetic to IVIG. Of note, the most common adverse reaction in 
patients that underwent fSCIG treatment was local reaction in the injection 
site, with a similar rate to SCIG. In contrast, fSCIG injections had a significant 
lower rate of systemic reactions compared to the IVIG[11]. During the 
extension study the frequency of systemic adverse reactions remained low and 
the rate of relater local adverse reactions decreased from 3.68/subject-year in 
months 1-12 to approximately 1.50/subject-year after 30 months of treatment. 
When comparing the pharmacokinetic profiles between the different infusion 
methods, fSCIG and IVIG had similar serum through levels, with a median of 10 
g/L and 10,4 g/L, respectively. Peak serum IgG levels were lower after fSCIG 
than after IVIG. Higher peak serum IgG levels might be responsible of the 
different systemic reaction rate between the two methods [12]. In addition, 
when comparing SCIG alone, fSCIG improved the drug bioavailability by 
approximately 20%. Figure 2 illustrates the pharmacokinetics of the IgG serum 
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levels different routes of administration of immunoglobulin replacement 
therapy.  
IVIG has been proven as efficacious for various autoimmune diseases and has 
been proposed to be a promising toll for the management of selected cases of 
pemphigus vulgaris[13]. The advantages of immunoglobulin therapy are 
relatively safe drug profile, especially important in the case presented, and 
ease of delivery, with only a single cycle per month. 
Due to the lack of available experience related to the use of fSCIG for 
immunomodualtory purpose, we applied the conventional protocol used for 
fSCIG as a replacement therapy in patients with hypogammaglobulinemia. 
fSCIG might further improve patient care, with home self-injections and 
significantly lower rate of systemic adverse reactions and might represent an 
important tool for the treatment of selected pemphigus vulgaris patients. 
Future studies will be needed to investigate fSCID infusion regimens (dosage 
and schedule) tailored for autoimmune conditions.  
 
 
LEARNING POINTS/TAKE HOME MESSAGES  
 
 
1- The use of immunoglobulin therapy for autoimmune conditions has been 
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proven and analyzed in numerous studies, but the use of fSCIG is yet to be 
investigated.  
2- We present the case of a patient with pemphigus vulgaris treated with 
fSCIG(25g) at monthly cycles with substantial decrease of the rate of bullous 
mucous lesions and improvement of time to lesion healing and resolution. 
3- fSCIG might further improve patient care, with home self-injections and 
significantly lower rate of systemic adverse reactions and might represent an 
important tool for the treatment of selected pemphigus vulgaris patients.  
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FIGURE/VIDEO CAPTIONS  
 
Figure 1.Resolution of a bullous oral lesion within two days. 
 
Figure 2. Pharmacokinetics of the IgG serum levels different routes of administration of 
immunoglobulin replacement therapy. Adapted from Wasserman et al [6]. 
 
 
Tables 
 
 
Table 1. Investigations undergone by the patient 
Blood count WBC 5740 (cells/µl), Neutrophils 4700/µl, Lymphocytes 780/µl, 
Monocytes 25/µl, Eosinophils50/µl, Basophiles 40/µl, RBC 
4,83X106/µl, Hb12.6 g/dl, MCV 81fL, PLTs 321000/µl 
Blood tests Immunoglobulins: IgG 1080/IgM 71/IgA 187, C3 68 mg/dl, C4 7 
mg/dl 
ANA neg, anti dsDNAneg, ANCA neg, cryoglobulinsneg, 
antiphospholipid antibodies neg,  rheumatoid factor 472 
HBV-DNA: neg; HCV-RNA: neg;  
normal complete urine test.  
 
Oral Mucosa 
biopsy  
Epithelium with cracks in deeper layers of malignant, 
acantolytic keratinocytes. Stroma slightly emaciated with 
small pervascular infiltrative lymphoestiocytic nodes. 
Direct Immunofluorescence: intracellular IgG +++, C3 to 
intercellular fluorescence +. 
Breast Cancer 
Histology 
Infiltrating ductal carcinoma, G2, maximum size 16 mm, 
lymphocyte invasion, MTS free sentinel lymph node, pT1c, pNo. ER 
99%, Prg 99%, Ki67 31%, HER2 score O. 
Abdominal Unremarkable 
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echography 
Chest radiography Unremarkable 
 
 
 
 
